Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Electronic Resource  (9)
  • 1995-1999  (4)
  • 1980-1984  (5)
  • 1
    Electronic Resource
    Electronic Resource
    Improved circular polarizer for far-infrared lightpipe systems (1995)
    [S.l.] : American Institute of Physics (AIP)
    Review of Scientific Instruments 66 (1995), S. 5559-5562 
    Details
    ISSN: 1089-7623
    Source: AIP Digital Archive
    Topics: Physics , Electrical Engineering, Measurement and Control Technology
    Notes: We present an improved design for far-infrared (FIR) circular polarizers used in a lightpipe transmission system for magneto-optical experiments. A peak efficiency of nearly 100% is achieved for FIR laser radiation by reducing the multiple reflections within the polarizer system, as well as scattering from the walls of the lightpipe. Broadband low-resolution measurements are less susceptible to errors due to multiple reflections, but incorporation of these improvements is still found to reduce systematic errors due to the reflection from the sample. Also, we have measured the low temperature index of refraction of quartz and find significant disagreement with published values for frequencies below 100 cm−1. © 1995 American Institute of Physics.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1063/1.1146084
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Failure of a Fluotec Mk II (1982)
    Oxford, UK : Blackwell Publishing Ltd
    Anaesthesia 37 (1982), S. 0 
    Details
    ISSN: 1365-2044
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: The sump of a Fluotec Mk II vaporiser separated from the upper portion of the vaporiser during an anaesthetic, and fell off. The danger to the patient is discussed, as well as the possible causes for this occurrence.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1111/j.1365-2044.1982.tb01857.x
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Effects of Long-Term Administration of Methotrexate on Bone Mineral Density in Rheumatoid Arthritis (1999)
    Springer
    Calcified tissue international 64 (1999), S. 100-101 
    Details
    ISSN: 1432-0827
    Keywords: Key words: Methotrexate — Bone loss — Rheumatoid arthritis.
    Source: Springer Online Journal Archives 1860-2000
    Topics: Biology , Medicine , Physics
    Notes: Abstract. Because previous studies of high-dose methotrexate usage have demonstrated an effect on bone formation and resorption, this study was done to determine whether long-term, low-dose use of methotrexate for the treatment of rheumatoid arthritis causes bone loss. Bone mineral density (BMD) of the lumbar spine and hip was measured in 10 Caucasian postmenopausal women who had never received methotrexate and 10 Caucasian postmenopausal women who had received the drug for 3 or more years. There were no significant differences in BMD at the lumbar spine (L2–L4) between patients who had used long-term methotrexate compared with patients never treated with methotrexate (1.08 ± 0.08 g/cm2 versus 0.98 ± 0.14 g/cm2, respectively; P= 0.08). Similarly, there were no significant differences in BMD at the femoral neck between methotrexate users and nonusers (0.81 ± 0.08 g/cm2 versus 0.76 ± 0.15 g/cm2, respectively; P= 0.42). These results suggest that long-term low-dose methotrexate treatment for rheumatoid arthritis is not associated with accelerated bone loss.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002239900585
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation (1997)
    Springer
    Annals of oncology 8 (1997), S. 604-606 
    Details
    ISSN: 1569-8041
    Keywords: JM216 ; lung cancer ; non-small cell ; oral chemotherapy ; platinum
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: JM216 is a new oral platinum complex with dose-limitingtoxicity myelosuppresssion, now undergoing phase II evaluation. Patients and methods: JM216 was evaluated as first line therapy innon-small-cell lung cancer. 17 patients received 120 mg/m2/dayfor five days repeated every three weeks. Results: Toxicity was manageable, the commonest side-effects being nausea,vomiting, diarrhoea, constipation and asthenia. Myelososuppression wasgenerally grade 〈2 and there were no cases of neutropenic sepsis orbleeding. Thirteen patients were fully evaluable for response. No sustainedobjective responses were reported. One patient was reported as stable diseasehad a partial response after three courses but was progressing again afterfour. An additional five patients had stable disease (46.2%). Conclusions: Although some patients may have had useful palliation, JM216did not appear to have significant antitumour activity in non-small-cell lungcancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008245709924
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses (1984)
    Springer
    Investigational new drugs 2 (1984), S. 281-286 
    Details
    ISSN: 1573-0646
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-four patients with a variety of solid tumors entered a Phase I trial with 4-demethoxydaunorubicin, a new analogue of daunorubicin. The drug was given as a single oral dose of 10–60 mg/m2 repeated every 3–4 weeks. Leukopenia was the dose-limiting toxicity. Other toxic effects included mild to moderate nausea and vomiting. Sixty mg/m2 was found to be the maximum tolerated dose in patients with fair tolerance to chemotherapy and normal liver function. Similar hematologic toxicity was reported in patients with very extensive prior chemotherapy or diffuse bone and/or liver metastases receiving 50 mg/m2. However, the wide range of the WBC nadirs reported with the same dose in ‘good risk’ cases, suggest that 40 mg/m2, increased up to 50 mg/m2 in the absence of significant myelotoxicity, could be more safely proposed as starting dose for Phase II trials. Pharmacokinetic studies were performed in five patients given a single dose of 40–60 mg/m2. IMI-30 (NSC 256439) appears to be rapidly absorbed and rapidly eliminated from plasma by means of a rapid and extensive biotransformation to 13-OH-idarubicin. The 13-dihydroderivative was present at higher and more prolonged levels than the parent compound, with an elimination half-life of about 40 hours.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00175378
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Phase I trial of 4′-deoxydoxorubicin given weekly (1984)
    Springer
    Investigational new drugs 2 (1984), S. 369-374 
    Details
    ISSN: 1573-0646
    Keywords: Phase I trial ; 4′-deoxydoxorubicin ; esorubicin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-six patients with various solid tumors entered a Phase I trial with 4′ -Deoxydoxorubicin (Esorubicin, IMI-58), a new doxorubicin analogue. The drug was administered weekly i.v. for 3–4 weeks. Leukopenia proved to be dose limiting. The maximum tolerated dose (MTD) was reached at 20 mg/m2 weekly for 3 weeks. For Phase II trials, a weekly dose of 15 and 17.5 mg/m2 can be proposed for poor and good risk patients respectively. Non-hematologic toxicity was minimal. Phase II trials with this new anthracycline are warranted.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00171587
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Biomaterial-neutrophil interactions: Dysregulation of oxidative functions of fresh neutrophils induced by prior neutrophil-biomaterial interaction (1996)
    Hoboken, NJ : Wiley-Blackwell
    Journal of Biomedical Materials Research 30 (1996), S. 67-75 
    Details
    ISSN: 0021-9304
    Keywords: Chemistry ; Polymer and Materials Science
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Medicine , Technology
    Notes: Biomaterial-associated infection results in increased morbidity and mortality, and may occur because of nonproductive premature activation of neutrophils resulting in impaired phagocyte function at the biomaterial surface in the event of bacterial challenge. To further explore the effects of this premature activation, we evaluated the supernatants of biomaterial associated neutrophils to determine whether soluble mediators were released, and the likely role of these mediators. We show that these supernatants contain a chemoattractant and thereby induce chemotaxis by fresh neutrophils. No evidence of enhanced oxidative free radical production by either unstimulated neutrophils or a primed response to other mediators occurs when neutrophils were incubated with these supernatants. We also examined the effect of adding fresh neutrophils to a biomaterial surface containing a previous inoculum of neutrophils, and observed that the fresh cells did not become stimulated to release reactive oxygen intermediates (ROI) and also exhibited impaired killing of staphylococci. These studies suggest that not only does the biomaterial surface activate the initial wave of neutrophils but that subsequent waves of neutrophils exhibit an impaired host-defense function. These results are consistent with the known impairment of host defense in the presence of biomaterials, and provide evidence for a long-term down-regulation of neutrophil function at biomaterial surfaces. © 1995 John Wiley & Sons, Inc.
    Additional Material: 5 Ill.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
  • 8
    Electronic Resource
    Electronic Resource
    A 13C-NMR investigation of plasma polymerized ethane, ethylene, and acetylene (1981)
    New York : Wiley-Blackwell
    Journal of Polymer Science: Polymer Chemistry Edition 19 (1981), S. 2987-2996 
    Details
    ISSN: 0360-6376
    Keywords: Physics ; Polymer and Materials Science
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology
    Notes: Solid-state 13C-NMR spectra were obtained by cross-polarization and magic angle spinning of polymers prepared by injecting ethane, ethylene, and acetylene into a radiofrequency plasma. By use of the delayed decoupling technique to suppress protonated carbon peaks and difference spectroscopy five resolved spectral bands can be distinguished. These bands are assigned to (I) unsaturated nonprotonated, (II) unsaturated CH and CH2, (III) quaternary, (IV) methine and methylene, and (V) methyl carbons by comparison with standard 13C shifts compiled for organic materials. The relative amounts of these structural features in the polymers were determined quantitatively and the possible sources of errors considered.
    Additional Material: 3 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/pol.1981.170191130
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    The structure of plasma-polymerized toluene: A solid-state 13C-NMR study of isotopically labeled polymers (1983)
    New York : Wiley-Blackwell
    Journal of Polymer Science: Polymer Chemistry Edition 21 (1983), S. 1819-1829 
    Details
    ISSN: 0360-6376
    Keywords: Physics ; Polymer and Materials Science
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology
    Notes: A detailed magic angle spinning 13C-NMR investigation of the intractable polymer prepared by plasma polymerization of toluene and isotopically labeled toluene led to a proposed model for the structure of the polymer and suggested some of the likely processes that occur in the gas phase leading to film formation. From the 13C spectra four resolved resonances permitted the determination of the contribution of nonprotonated and protonated unsaturated as well as methyl and other aliphatic carbons to the polymer structure. Specific 13C isotopic labeling of the methyl and phenyl C-1 toluene carbons in the injected liquid vapor allowed the destination of these carbons in the deposited polymer to be traced. The dominant structure is derived primarily from two precursors: benzyl radical and toluene itself. The 13C data further requires a net saturation of ca. 30% of the toluene double bonds and a net displacement of hydrogen by carbon on ca. 20% of the toluene ring carbons.
    Additional Material: 5 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/pol.1983.170210622
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...